<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50282">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01907529</url>
  </required_header>
  <id_info>
    <org_study_id>HBMUFH-101</org_study_id>
    <nct_id>NCT01907529</nct_id>
  </id_info>
  <brief_title>A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer</brief_title>
  <acronym>TENDENCY</acronym>
  <official_title>A Trail of Neoadjuvant Endostar in Combination With Docetaxel, Epirubicin and Cyclophosphamide in Patients With Stage III Breast Cancer (TENDENCY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University Fourth Hospital</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial was designed to study the efficacy and safety of neoadjuvant docetaxel, epirubicin
      in combination with cyclophosphamide(DEC) plus human recombinant endostatin (endostar) for
      breast cancer patients. The hypothesis of this protocol is that the combined an active
      angiogenesis agent to chemotherapy could enhance the pathological responce rate and further
      benefit breast cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical/pathological response</measure>
    <time_frame>48 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The clincial response will be evaluated according to RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Stage III Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Chemo plus Endostar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel, epirubicin and cyclophosphamide plus endostar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemo only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel, epirubicin and cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, epirubicin and cyclophosphamide</intervention_name>
    <description>docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; totally 4 cycles</description>
    <arm_group_label>Chemo only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, epirubicin and cyclophosphamide plus endostar</intervention_name>
    <description>docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostar 7.5mg/m2, IV (in the vein) from day 1 to day 14, totally 4 cycles</description>
    <arm_group_label>Chemo plus Endostar</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed invasive breast cancer (core needle biopsy for breast cancer
             diagnosis and fine needle aspiration for lymph node metastasis diagnosis)

          -  Age 18-70

          -  No evidence of distant metastasis

          -  No previous therapy

          -  Normal hematologic function

          -  No abnormality of renal or liver function

          -  Written informed consent

        Exclusion Criteria:

          -  With allergic constitution or possible allergic reflection to drugs to be used in
             this study

          -  Any concurrent uncontrolled medical or psychiatric disorder

          -  History of severe heart diseases, including congestive heart failure, unstable
             angina, uncontrolled arrhythmia, myocardial infarction, uncontrolled high blood
             pressure, or heart valve disease

          -  Being pregnant or nursing
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YUNJIANG LIU, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Medical University Fourth Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunjiang Liu, M.D</last_name>
    <phone>12703297890</phone>
    <email>lyj818326@126.com</email>
  </overall_contact>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 22, 2013</lastchanged_date>
  <firstreceived_date>July 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University Fourth Hospital</investigator_affiliation>
    <investigator_full_name>Yunjiang Liu</investigator_full_name>
    <investigator_title>M.D, Chief Physician of Breast Cancer Dept, Vice-President of Hebei Medical University Fourth Hospital</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
